Results 1 to 10 of about 5,389 (186)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy [PDF]

Case Reports in Gastroenterology, 2022
Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied.
Aaron G. Issac, David Szafron, Dongguang Wei, Jennifer L. McQuade, Yinghong Wang   +4 more
doaj   +3 more sources

The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis [PDF]

Discover Oncology
Purpose Brain metastases (BMs) present a significant therapeutic challenge due to limited blood-brain barrier permeability, which restricts the efficacy of systemic treatments.
Amirmohammad Bahri, Ali Dehghan Banadaki, Mobina Bayani, Ibrahim Mohammadzadeh, Milad Shafizadeh, Mohammad Amin Habibi, Bardia Hajikarimloo   +6 more
doaj   +2 more sources

and inhibition as treatment strategies in V600E metastatic colorectal cancer [PDF]

Therapeutic Advances in Medical Oncology, 2021
Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling.
Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez   +10 more
doaj   +2 more sources

Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer [PDF]

Neoplasia: An International Journal for Oncology Research
The presence of BRAFV600E mutations is associated with poor prognosis in colorectal cancer (CRC). Although the FDA-approved combination of encorafenib and cetuximab provides clinical benefit in this population, only 22% of patients respond and most ...
Mariah E. Geisen, Josiane W. Tessmann, Courtney O. Kelson, Daheng He, Chi Wang, Abu Saleh Mosa Faisal, Ellen J. Beswick, Yasmine Baca, Stephanie Rock, Jill M. Kolesar, Yekaterina Y. Zaytseva   +10 more
doaj   +2 more sources

Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis [PDF]

Current Oncology
Background: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting.
Matthew Dankner, Laurie-Rose Dubé, Mark Sorin, Andrew J. B. Stein, Alexander Nowakowski, Changsu Lawrence Park, Jamie Magrill, Anna-Maria Lazaratos, Joan Miguel Romero, Gerald Batist, Petr Kavan, April A. N. Rose, Kim Ma   +12 more
doaj   +2 more sources

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E) [PDF]

Oncogenesis
The oncogenic BRAF(V600E) mutation activates the ERK1/2 pathway and is detected in 10% of human colorectal cancers (CRCs) where it is associated with poor prognosis. Inhibitors of BRAF have shown only modest efficacy in patients with CRC due to intrinsic
Md Mohiuddin, Vanda Póvoa, Rita Fior, Frank A. Sinicrope   +3 more
doaj   +2 more sources

Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells [PDF]

Scientific Reports
The current study established the first in vitro Encorafenib resistance protocol in BRAF-mutated malignant melanoma (MM) cells and investigated the resistance-related mechanisms.
Ceyda Colakoglu Bergel, Isil Ezgi Eryilmaz, Gulsah Cecener, Unal Egeli   +3 more
doaj   +2 more sources

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary. [PDF]

Future Oncol
Chemotherapy; Metastatic colorectal cancer; MutationQuimioterapia; Cáncer colorrectal metastásico; MutaciónQuimioteràpia; Càncer colorectal metastàtic; MutacióWhat is this summary about?BRAF V600E-mutant metastatic colorectal cancer is difficult to treat
Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J.   +14 more
europepmc   +3 more sources

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. [PDF]

Clin Cancer Res
Targeted therapy; Metastatic melanoma; BRAFV600-mutantTeràpia dirigida; Melanoma metastàtic; Mutació BRAFV600Terapia dirigida; Melanoma metastásico; Mutación BRAFV600Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study ...
Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Muñoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA.   +20 more
europepmc   +3 more sources

A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study. [PDF]

Future Oncol
Colorectal cancer; MutationCàncer colorectal; MutacióCáncer colorrectal; MutaciónWhat is this summary about? This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were ...
Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J.   +13 more
europepmc   +3 more sources